Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2007

View Archived Issues

Novel neurologic compounds disclosed in recent UCB and NeuroSearch patents

Recent Otsuka and Basilea patents claim novel therapeutic agents for dermatological disorders

Novel treatment option for sepsis disclosed in recent patent

PKC-delta: a new target for the treatment of hepatic insulin resistance

MK-0364, MK-0493 studied in obese subjects

Snapshots of miscellaneous treatments for diabetes from the ADA meeting

Algeta enters new collaboration to expand TH-1 targeted cancer therapy program

Phosphodiesterases identified as potential targets in migraine

Targets in migraine: CGRP antagonists

Orexin system involved in headache pathogenesis

New clinical information on R-115866 and adalimumab in psoriasis

Tetravalent dengue vaccine protects against dengue virus infection in macaques

BioDelivery Sciences completes pre-NDA meeting with FDA

Bioalliance licenses Loramyc to Par Pharmaceutical

Positive phase I results for Acrux's combination contraceptive spray

Biogen Idec and Cardiokine to codevelop lixivaptan for hyponatremia

GTx evaluates Ostarine in phase IIb for treatment of cancer cachexia

Biomira files IND for phase I trial of HIF-1 alpha inhibitor PX-478

Recent Auspex patent discloses new treatment option for substance abuse and dependence

Pediatric study evaluates vaccine to prevent RSV and PIV-3 infections

Phase II study of A-002 completes enrollment

Promising results of novel live attenuated vaccine against salmonellosis infection

Nanocarrier-based long-acting GLP-1 mimetic improves blood glucose control in diabetic rats

Japanese approval sought for mirtazapine

Kyoto University and Astellas Pharma to coresearch immunoregulation drugs

FDA agrees on SPA for crofelemer phase III trial

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...